Exploring the mechanism of action of QUVIVIQ™
Promotional material from Idorsia Pharmaceuticals UK Ltd.
References
1 – QUVIVIQ™ Idorsia Pharmaceuticals Ltd, summary of product characteristics.
2 – Roch C, et al. Psychopharmacology. 2021; 238(10): 2693–2708.
3 – NICE Clinical Knowledge Summary (CKS) Insomnia: Scenario: Managing long-term insomnia (more than 3 months duration). Available at: https://cks.nice.org.uk/topics/insomnia/management/managing-insomnia/. Updated May 2025. Accessed June 2025.
4 – Mignot E, et al. Lancet Neurol. 2022; 21(2): 125–139.
5 – Robbins R, et al. Front Sleep. 2022; 1: 935228.
6 – Di Marco T, et al. CNS Drugs. 2023; 37(7): 639–653.
7 – Kunz D, et al. CNS Drugs. 2022; 37(1): 93–106.
8 – Chaput JP, et al. Nat Sci Sleep. 2018; 10: 421–430.
This information is intended for UK healthcare professionals.
Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google play or Apple App store. Adverse events should also be reported to ds.safety.uk@idorsia.com.